{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:16:32Z","timestamp":1791893792961,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2007,1,26]],"date-time":"2007-01-26T00:00:00Z","timestamp":1169769600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2007,3,19]]},"DOI":"10.1007\/s00280-006-0332-4","type":"journal-article","created":{"date-parts":[[2007,1,25]],"date-time":"2007-01-25T10:33:58Z","timestamp":1169721238000},"page":"771-779","source":"Crossref","is-referenced-by-count":12,"title":["High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study"],"prefix":"10.1007","volume":"59","author":[{"given":"Alessandra","family":"Tedeschi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Montillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Strocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Cafro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Tresoldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Intropido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Nichelatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Marbello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Barat\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Maurizio","family":"Camaggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Morra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,1,26]]},"reference":[{"key":"332_CR1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0889-8588(18)30261-2","volume":"7","author":"D Hoelzer","year":"1993","unstructured":"Hoelzer D (1993) Therapy of the newly diagnosed adult with acute lymphoblastic leukemia. Hematol Oncol Clin North Am 7:139\u2013160","journal-title":"Hematol Oncol Clin North Am"},{"key":"332_CR2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0889-8588(05)70204-5","volume":"15","author":"G Garcia-Manero","year":"2001","unstructured":"Garcia-Manero G, Thomas DA (2001) Salvage therapy for refractory or relapsed adult acute lymphoblastic leukemia. Hematol Oncol Clin North Am 15:163\u2013205","journal-title":"Hematol Oncol Clin North Am"},{"key":"332_CR3","first-page":"S28","volume":"11","author":"MA Weiss","year":"1997","unstructured":"Weiss MA (1997) Treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL). Leukemia 11:S28\u2013S30","journal-title":"Leukemia"},{"key":"332_CR4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0145-2126(99)00180-0","volume":"24","author":"EJ Feldaman","year":"2000","unstructured":"Feldaman EJ (2000) High-dose cytarabine-based therapy in adults with acute lymphoblastic leukemia. Leuk Res 24:189\u2013191","journal-title":"Leuk Res"},{"key":"332_CR5","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ajh.2830450413","volume":"45","author":"JL Welborn","year":"1994","unstructured":"Welborn JL (1994) Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults. Am J Hematol 45:341\u2013344","journal-title":"Am J Hematol"},{"key":"332_CR6","first-page":"694","volume":"63","author":"RL Capizzi","year":"1984","unstructured":"Capizzi RL, Poole M, Cooper MR, Richards F 2nd, Stuart JJ, Jackson DV, White DR, Spurr CL, Hopkins JO, Muss HB (1984) Treatment of poor risk acute leukemia with sequential high-dose Ara-C and asparaginase. Blood 63:694\u2013700","journal-title":"Blood"},{"key":"332_CR7","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3109\/10428199709039047","volume":"25","author":"M Montillo","year":"1997","unstructured":"Montillo M, Tedeschi A, Centurioni R, Leoni P (1997) Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte coloni-stimulating factor (FLAG-G-CSF). Leuk Lymphoma 25:579\u2013583","journal-title":"Leuk Lymphoma"},{"key":"332_CR8","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/blood.V72.2.433.bloodjournal722433","volume":"72","author":"Z Arlin","year":"1988","unstructured":"Arlin Z, Feldman E, Kempin S, Ahmed T, Mittelman A, Savona S, Ascensao J, Baskind P, Sullivan P, Fuhr HG (1988) Amsacrine with high-dose cytarabine is highly effective therapy for refractory and relapsed acute lymphoblastic leukemia in adults. Blood 72:433\u2013435","journal-title":"Blood"},{"key":"332_CR9","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/1097-0142(19931001)72:7<2155::AID-CNCR2820720715>3.0.CO;2-V","volume":"72","author":"S Suki","year":"1993","unstructured":"Suki S, Kantarjian H, Gandhi V, Estey E, O\u2019Brien S, Beran M, Rios MB, Plunkett W, Keating M (1993) Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed adult acute lymphocytic leukemia. Cancer 72:2155\u20132160","journal-title":"Cancer"},{"key":"332_CR10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/1097-0142(19900101)65:1<5::AID-CNCR2820650104>3.0.CO;2-R","volume":"65","author":"HM Kantarjian","year":"1990","unstructured":"Kantarjian HM, Walters RS, Keating MJ, Estey EH, O\u2019Brien S, Schachner J, McCredie KB, Freireich EJ (1990) Mitoxantrone and high dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia. Cancer 65:5\u20138","journal-title":"Cancer"},{"key":"332_CR11","first-page":"637","volume":"4","author":"W Hiddeman","year":"1990","unstructured":"Hiddeman W, Buchner T, Heil G, Schumacher K, Diedrich H, Maschmeyer G, Ho AD, Planker M, Gerith-Stolzemburg S, Donhuijsen-Ant R (1990) Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytarabine and mitoxantrone (HAM). Leukemia 4:637\u2013640","journal-title":"Leukemia"},{"key":"332_CR12","first-page":"712","volume":"5","author":"ZA Arlin","year":"1991","unstructured":"Arlin ZA, Feldman EJ, Finger LR, Ahmed T, Mittelman A, Cook P, Puccio C, Baskind P, Arnold P, RAzis ED (1991) Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia. Leukemia 5:712\u2013714","journal-title":"Leukemia"},{"key":"332_CR13","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0145-2126(99)00078-8","volume":"23","author":"P Raanani","year":"1999","unstructured":"Raanani P, Shpilberg O, Gillis S, Avigdor A, Hardan I, Berkowicz M, Sofer O, Lossos I, Chetrit A, Ben-Yehuda D, Ben-Bassat I (1999) Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine. Leuk Res 23:695\u2013700","journal-title":"Leuk Res"},{"key":"332_CR14","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/sj.leu.2401058","volume":"12","author":"MA Weiss","year":"1998","unstructured":"Weiss MA, Drullinsky P, Maslak P, Scheinberg D, Golde DW (1998) A phase I trial of a single high dose of idarubicin combined with high dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia. Leukemia 12:865\u2013868","journal-title":"Leukemia"},{"key":"332_CR15","first-page":"80","volume":"35","author":"P Borchmann","year":"1997","unstructured":"Borchmann P, Hubel K, Schnell R, Engert A (1997) Idarubicin: a brief overview on pharmacology and clinical use. Int J Clin Pharmacol Ther 35:80\u201383","journal-title":"Int J Clin Pharmacol Ther"},{"key":"332_CR16","first-page":"707","volume":"10","author":"E Schleyer","year":"1996","unstructured":"Schleyer E, Kuhn S, Ruhrs H, Unterhalt M, Kaufmann CC, Kem W, Braess J, Straubel G, Hiddeman W (1996) Oral idarubicin pharmacokinetics-correlation of through level with idarubicin area under the curve. Leukemia 10:707\u2013712","journal-title":"Leukemia"},{"key":"332_CR17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF00686301","volume":"30","author":"CM Camaggi","year":"1992","unstructured":"Camaggi CM, Strocchi E, Carisi P, Maltoni A, Tononi A, Guaraldi M, Strolin-Benedetti M, Efthymopoulos C, Pannuti F (1992) Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. Cancer Chem Pharmacol 30:307\u2013316","journal-title":"Cancer Chem Pharmacol"},{"key":"332_CR18","volume-title":"Common toxicity criteria","author":"National Cancer Institute, Division of Cancer Treatment","year":"1998","unstructured":"National Cancer Institute, Division of Cancer Treatment (1998) Common toxicity criteria. National Cancer Institute, Bethesda"},{"key":"332_CR19","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","volume":"19","author":"H Akaike","year":"1974","unstructured":"Akaike H (1974) A new look at the statistical model identification. IEEE Trans Automatic Control 19:716\u2013723","journal-title":"IEEE Trans Automatic Control"},{"key":"332_CR20","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V99.3.863","volume":"99","author":"L Annino","year":"2002","unstructured":"Annino L, Vegna ML, Camera A, Specchia G, Visani G, Fioritoni G, Ferrara F, Peta A, Ciolli S, Deplano W, Fabbiano F, Sica S, Di Raimondo F, Cascavilla N, Tabilio A, Leoni P, Invernizzi R, Baccarani M, Rotoli B, Amadori S, Mandelli F (2002) Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL-0288 randomized study. The GIMEMA group. Blood 99:863\u2013871","journal-title":"Blood"},{"key":"332_CR21","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1182\/blood-2002-12-3822","volume":"102","author":"G Cimino","year":"2003","unstructured":"Cimino G, Elia L, Mancini M, Annino L, Anaclerico B, Fazi P, Vitale A, Specchia G, Di Raimondo F, Recchia A, Cuneo A, Mecucci C, Pane F, Saglio G, Foa R, Mandelli F (2003) Clinico-biologic features and treatment outcome of adult pro-B-ALL patients enrolled in the GIMEMA 0496 study absence of the ALL1\/AF4 and of the BCR\/ABL fusion genes correlates with a significantly better clinical outcome. Blood 102:2014\u20132020","journal-title":"Blood"},{"key":"332_CR22","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S0889-8588(05)70188-X","volume":"14","author":"N Gokbuget","year":"2000","unstructured":"Gokbuget N, Hoelzer D, Arnold R, Bohme A, Bartram CR, Freund M, Ganser A, Kneba M, Langer W, Lipp T, Ludwig WD, Mashmeyer G, Rieder H, Thiel E, Weiss A, Messerer D (2000) Treatment of adult ALL according to protocols of the German Multicenter Study Group for adult ALL (GMALL). Hematol Oncol Clin North Am 14:1307\u20131325","journal-title":"Hematol Oncol Clin North Am"},{"issue":"10 Suppl","key":"332_CR23","first-page":"20","volume":"86","author":"L Annino","year":"2001","unstructured":"Annino L, Fazi P, Specchia G (2001) Mitoxantrone in the induction treatment of adult acute lymphoblastic leukemia: GIMEMA phase II pilot study. Hematologica 86(10 Suppl):20","journal-title":"Hematologica"},{"key":"332_CR24","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1046\/j.1365-2141.1997.1102926.x","volume":"97","author":"F Giona","year":"1997","unstructured":"Giona F, Annino L, Rondelli R, Arcese W, Meloni G, Testi AM, Moleti ML, Amadori S, Resegotti L, Tabilio A, LAdogana S, Fioritoni G, Camera A, Liso V, Leoni P, Mandelli F (1997) Treatment of adults with acute lymphoblastic leukemia in first bone marrow relapse. Results of the ALL R-87 protocol. Br J Haematol 97:896\u2013903","journal-title":"Br J Haematol"},{"key":"332_CR25","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/cncr.10707","volume":"95","author":"MA Weiss","year":"2002","unstructured":"Weiss MA, Aliff TB, Tallman MS, Frankel SR, Kalaycio ME, Maslak PG, Jurcic JG, Scheinberg DA, Roma TE (2002) A single high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia. Cancer 95:581\u2013587","journal-title":"Cancer"},{"key":"332_CR26","first-page":"145","volume":"89","author":"A Camera","year":"2004","unstructured":"Camera A, Annino L, Chiurazi F, Fazi P, Cascavilla N, Fabbiano F, Marmont F, Di Raimondo F, Recchia A, Vignetti M, Rotoli B, MAndelli F (2004) GIMEMA ALL-Rescue 97: a salvage strategy for primary refractory or relapsed adult acute lymphoblastic leukemia. Haematologica 89:145\u2013153","journal-title":"Haematologica"},{"key":"332_CR27","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1046\/j.1365-2141.2002.03706.x","volume":"118","author":"AM Testi","year":"2002","unstructured":"Testi AM, Del Giudice I, Arcese W, Moleti ML, Giona F, Basso G, Biondi A, Conter V, Messina C, Rondelli R, Micozzi A, Micalizzi C, Barisone E, Locatelli F, Dini G, Arico M, Casale F, Comis M, Ladogana S, Lippi A, Mura R, Pinta MF, Santoro N, Valsecchi MG, Masera G, Mandelli F (2002) A single high dose of idarubicin combined with high-dose Ara-C for treatment of first relapse childhood \u2018high-risk\u2019 acute lymphoblastic leukemia: a study of the AIEOP group. Br J Haematol 118:741\u2013747","journal-title":"Br J Haematol"},{"key":"332_CR28","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O","volume":"86","author":"DA Thomas","year":"1999","unstructured":"Thomas DA, Kantarjian H, Smith TL, Koller C, Cortes J, O\u2019Brien S, Giles FJ, Gaiewski J, Pierce S, Keating MJ (1999) Primary refractory and relapsed adult acute lymphoblastic leukemia, characteristics, treatment results and prognosis with salvage therapy. Cancer 86:1216\u20131230","journal-title":"Cancer"},{"key":"332_CR29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ctrv.2003.07.003","volume":"30","author":"KJ Schimmel","year":"2004","unstructured":"Schimmel KJ, Richel DJ, van den Brimk RB, Guchelaar HJ (2004) Cardiotoxicitty of cytotoxic drugs. Cancer Treat Rev 30:181\u2013191","journal-title":"Cancer Treat Rev"},{"key":"332_CR30","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/cncr.20494","volume":"101","author":"M Karbasian-Esfahani","year":"2004","unstructured":"Karbasian-Esfahani M, Wiernik PH, Novik Y, Paietta E, Dutcher JP (2004) Idarubicin and standard doser cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia. Cancer 101:1414\u20131419","journal-title":"Cancer"},{"key":"332_CR31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.bmt.1703827","volume":"31","author":"C Bengala","year":"2003","unstructured":"Bengala C, Danesi R, Guarneri V, Pazzagli I, Donati S, Favre C, Fogli S, Biadi O, Innocenti F, Del Tacca M, Mariani M, Conte PF (2003) High-dose consolidation chemotherapy with idarubicin and alkylating agents following induction with gemcitabine\u2013epirubicin\u2013paclitaxel in metastatic breast cancer: a dose finding study. Bone Marrow Transplant 31:275\u2013280","journal-title":"Bone Marrow Transplant"},{"key":"332_CR32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00043426-199901000-00006","volume":"21","author":"SL Berg","year":"1999","unstructured":"Berg SL, Reid J, Godwin K, Murry DJ, Poplack DG, Balis FM, Ames MM (1999) Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin and their metabolites in the nonhuman primate model. J Pediatr Hematol Oncol 21:26\u201330","journal-title":"J Pediatr Hematol Oncol"},{"key":"332_CR33","first-page":"6525","volume":"50","author":"JM Reid","year":"1990","unstructured":"Reid JM, Pendergrass TW, Krailo MD, Hammond GD, Ames MM (1990) Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report. Cancer Res 50:6525\u20136528","journal-title":"Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-006-0332-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-006-0332-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-006-0332-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T21:59:51Z","timestamp":1587333591000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-006-0332-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,26]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,3,19]]}},"alternative-id":["332"],"URL":"https:\/\/doi.org\/10.1007\/s00280-006-0332-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,26]]}}}